Preimplantation Genetic Testing Market Outlook: Size, Share & Trends Through 2034
The global preimplantation genetic testing market is entering a period of strong expansion as fertility clinics, genetic laboratories, and prospective parents increasingly adopt advanced testing solutions to identify genetic abnormalities before embryo implantation. Rising infertility rates, growing awareness of inherited disorders, and continuous progress in reproductive medicine are creating new opportunities for market participants. According to the latest market data, the global preimplantation genetic testing market was valued at $0.91 billion in 2025 and is projected to reach $2.01 billion by 2034, expanding at a CAGR of 9.23% during the forecast period from 2026 to 2034. Market Size (2025): $0.91 Billion Market Size (2026): $0.99 Billion CAGR (Forecast Period): 9.23% (2026-2034) Forecast Year: 2034 Projected Market Size (Forecast Year): $2.01 Billion Dominant Region: North America Fastest Growing Region: Asia Pacific Market Overview Preimplantation genetic testing (PGT) has become an important component of assisted reproductive technology (ART), allowing embryos created through in vitro fertilisation (IVF) to be evaluated for specific genetic and chromosomal abnormalities before implantation. The approach supports couples who are at risk of passing inherited conditions to their children and helps fertility specialists make more informed embryo selection decisions. The market is benefiting from the growing use of next-generation sequencing (NGS), polymerase chain reaction (PCR), and other molecular testing technologies. These innovations have improved testing accuracy, increased analytical capabilities, and supported faster laboratory workflows. Delayed parenthood in developed economies is also contributing to market demand, as advanced maternal age is associated with a higher risk of chromosomal abnormalities. At the same time, growing interest in personalised reproductive care is encouraging more patients to consider genetic screening as part of fertility treatment. Growth Drivers The increasing prevalence and awareness of genetic disorders represent a major growth driver for the preimplantation genetic testing market. Families with a history of inherited conditions are increasingly exploring reproductive genetic testing to reduce the possibility of transmitting specific disorders to their children. PGT can help identify embryos carrying certain genetic abnormalities before implantation, making it an important option for couples undergoing fertility treatment. Greater access to genetic counselling and improved public awareness are also helping patients understand available reproductive choices. Technological development is another important factor supporting market growth. NGS enables comprehensive analysis of genetic material and can identify a broad range of chromosomal and genetic abnormalities. As sequencing costs decline and testing platforms become more efficient, the use of advanced genetic screening in fertility clinics is expected to expand. The integration of artificial intelligence and automation is adding another layer of innovation. AI-powered systems can assist with genetic data interpretation, embryo assessment, and laboratory decision-making, while automation can reduce manual intervention and improve workflow consistency. Challenges Despite strong growth prospects, ethical and regulatory issues remain important challenges for the PGT industry. Questions surrounding embryo selection, the potential misuse of genetic testing for non-medical purposes, and concerns about the development of so-called "designer babies" continue to influence public and regulatory discussions. Regulations also differ significantly between countries. While some jurisdictions allow PGT for the prevention of serious inherited diseases, others impose strict limitations on its use. These differences can create complexities for international fertility providers and genetic testing companies. The high cost of IVF and genetic testing can also limit access. In many markets, insurance coverage for PGT remains restricted, making treatment less affordable for patients without sufficient financial resources. Greater regulatory clarity, responsible clinical practices, and broader access to genetic counselling will be important for sustainable market development. Opportunities Emerging economies are creating significant opportunities for PGT providers. Countries across Asia Pacific, including India and China, are witnessing increased demand for ART services as infertility awareness rises and healthcare infrastructure improves. Growing investment in fertility clinics and reproductive diagnostics is creating a larger addressable patient base. In addition, the expansion of advanced laboratories and greater availability of NGS-based testing are helping bring sophisticated genetic screening capabilities to new markets. The increasing use of AI and automation also presents a major opportunity. AI-assisted embryo imaging and automated laboratory workflows could improve operational efficiency and help fertility specialists evaluate embryos more consistently. As these technologies mature, their integration with genetic testing platforms may support faster turnaround times and broader access to reproductive genetic services. Segment Analysis By procedure, preimplantation genetic diagnosis (PGD) represents a leading segment. PGD is particularly valuable for couples with a known risk of transmitting specific inherited genetic conditions. Continued advances in molecular diagnostics and increasing demand for personalised reproductive care are expected to support the segment's development. By product, reagents and consumables hold a significant position due to their essential role in genetic testing workflows. DNA amplification materials, sequencing reagents, and other laboratory supplies are repeatedly required as PGT procedures increase. The development of consumables designed for automated and high-throughput systems is further supporting demand. By technology, next-generation sequencing (NGS) is a major growth area. The technology allows laboratories to analyse genetic material at high throughput and detect multiple types of abnormalities. Ongoing improvements in sequencing efficiency and affordability are expected to encourage broader adoption. By application, aneuploidy screening is a key segment. The procedure helps identify embryos with abnormal chromosome numbers, which may affect implantation and pregnancy outcomes. Rising maternal age and growing awareness of chromosomal abnormalities are supporting demand for aneuploidy screening. By end-user, fertility centres account for a leading share of the market. These facilities increasingly integrate genetic testing into IVF workflows to support embryo selection and reproductive outcomes. Partnerships between fertility clinics and specialised genetic testing providers are also helping streamline testing services. Regional Analysis North America remains the dominant regional market for preimplantation genetic testing. The region benefits from advanced healthcare infrastructure, high IVF adoption, strong research capabilities, and widespread access to reproductive genetic services. The United States represents a particularly important market due to its established fertility clinic network and continued investment in genetic testing technologies. The U.S. market is supported by increasing patient awareness, technological innovation, and collaboration between fertility providers and genetic testing companies. Canada is also experiencing steady development as awareness of reproductive genetics increases and investments in fertility research continue. Asia Pacific is projected to be the fastest-growing region during the forecast period. Rising infertility rates, expanding fertility clinic networks, improving healthcare infrastructure, and increasing awareness of genetic disorders are driving demand across the region. China is experiencing growing interest in ART and genetic diagnostics, supported by healthcare modernisation and investments in reproductive medicine. India is also emerging as an important market, with expanding fertility services, increasing healthcare expenditure, and rising demand for advanced reproductive technologies. Japan and South Korea are further contributing to regional growth through investments in laboratory automation and advanced IVF technologies. Europe represents another significant market, with countries such as the UK, Germany, and France supporting demand through established healthcare systems and strong research ecosystems. The region's structured regulatory environment and continued development of reproductive medicine are contributing to market growth. Competitive Landscape The global preimplantation genetic testing market is competitive, with companies focusing on technological innovation, strategic collaborations, portfolio expansion, and improvements in testing efficiency. Leading participants are investing in sequencing platforms, genetic analysis solutions, laboratory technologies, and reproductive health services to strengthen their positions. Key companies operating in the preimplantation genetic testing market include: Oxford Gene Technology Thermo Fisher Scientific Inc. SciGene Corporation Agilent Technologies Inc. PerkinElmer Inc. CooperSurgical Inc. Abbott Laboratories Illumina Inc. Natera Inc. Yikon Genomics Companies are increasingly concentrating on improving genetic analysis accuracy and integrating advanced technologies into fertility workflows. Partnerships between genetic testing providers and fertility centres are also helping expand access to specialised reproductive diagnostics. Recent Developments June 2026: Illumina continued advancing its reproductive health genomics initiatives, focusing on NGS-based solutions that support embryo genetic screening workflows. The company also continued collaborations with fertility laboratories aimed at improving the scalability and efficiency of genomic testing. May 2026: Natera advanced its reproductive health testing portfolio through continued development of embryo screening and genomic analysis capabilities designed to support fertility clinics and ART providers. March 2026: CooperSurgical expanded its fertility technology portfolio with further enhancements to laboratory solutions and services supporting IVF and PGT procedures. January 2026: Vitrolife continued developing IVF laboratory solutions and reproductive health technologies that support embryo assessment and genetic testing workflows. November 2023: Illumina introduced the VeriSeq PGS 3.0 platform, targeting improved efficiency and accuracy in genetic assessment during embryo selection for IVF. Future Outlook The global preimplantation genetic testing market is expected to maintain strong growth through 2034 as reproductive medicine becomes increasingly technology-driven. The combination of rising infertility, greater awareness of inherited diseases, and advances in genomic testing will continue to create demand for PGT solutions. AI, automation, and NGS are expected to remain central to future innovation. These technologies can improve testing workflows, support more detailed genetic analysis, and enhance the integration of laboratory data into fertility treatment decisions. Asia Pacific is likely to provide some of the most attractive expansion opportunities as fertility infrastructure develops and access to advanced reproductive diagnostics improves. Meanwhile, North America is expected to retain its leading position due to its established healthcare ecosystem and high adoption of genetic technologies. As regulations evolve and testing becomes more accessible, the market will increasingly focus on responsible implementation, patient education, affordability, and clinical reliability. These factors will shape the next phase of growth and help position PGT as an increasingly important part of personalised reproductive healthcare. Click to Read the Complete Insights & Report: https://straitsresearch.com/report/preimplantation-genetic-testing-market About Straits Research Straits Research is a global market intelligence and consulting company that provides comprehensive research reports, industry insights, and strategic analysis across a wide range of sectors. The company delivers data-driven market intelligence designed to help businesses, investors, and industry stakeholders understand emerging trends, assess growth opportunities, evaluate competitive landscapes, and make informed strategic decisions. Through detailed research methodologies and industry expertise, Straits Research supports organisations in navigating evolving markets and identifying opportunities for sustainable growth.